Vestibo 16mg 30 tablets — Made in Bulgaria — Free Delivery

Vestibo is indicated for the treatment of Meniere's disease and syndrome characterized by three main symptoms:

Vestibo is also prescribed for the symptomatic treatment of vestibular vertigo of various origins.

Hypersensitivity to or to any of the excipients of the preparation.

Pheochromocytoma.

Use during pregnancy or lactation

Pregnancy. There are insufficient data on the use of betahistine in pregnant women.

The results of animal studies are insufficient to assess the effect on pregnancy, embryo/fetal development, childbirth and postnatal development. The potential risk to humans is unknown. Betahistine should not be used during pregnancy unless clearly necessary.

breastfeeding period. It is not known whether betahistine passes into breast milk. Animal studies on the penetration of betahistine into milk have not been conducted. The benefit to the mother should be weighed against the benefits of breastfeeding and the potential risk to the baby.

Due to the lack of data on the safety and efficacy of betahistine, the preparation is not recommended for children (under the age of 18 years).

The ability to influence the reaction rate when driving vehicles or operating other mechanisms

Betahistine is indicated for the treatment of Meniere's syndrome, which is characterized by a triad of main symptoms: dizziness, hearing loss, tinnitus, as well as for the symptomatic treatment of vestibular vertigo. Both conditions can negatively affect the ability to drive and use machines. According to clinical studies that studied the effect on the ability to drive a car and work with other mechanisms, betahistine did not affect or had an insignificant effect on this ability.

The daily dose for adults is 24-48 mg, evenly distributed for admission during the day.

The dose should be selected individually, depending on the effect. Reduction of symptoms is sometimes observed only after two to three weeks of treatment. The best results are sometimes achieved when taking the preparation for several months. There is evidence that treatment early in the disease prevents disease progression and/or hearing loss in later stages.

There are several cases of preparation overdose. Some patients experienced mild to moderate symptoms (nausea, drowsiness, abdominal pain) after taking the preparation at a dose of up to 640 mg. More serious complications (convulsions, cardiopulmonary complications) have been observed with the deliberate intake of high doses of betahistine, especially in combination with an overdose of other preparations.